Pediatric Psoriasis Study
Study of Risankizumab in Pediatric Patients with Moderate to Severe Plaque Psoriasis
SEX AT BIRTH: All
CONDITION: Plaque psoriasis
LOCATION: University Hospitals Medical Centers
The purpose of this study is to evaluate Risankizumab compared to Ustekinumab for the treatment of moderate to severe plaque psoriasis who are pediatric candidates for systemic therapy.
Who Can Participate
Participants between 6 and 18 years old with diagnosed with plaque psoriasis and do not have prior exposure to biologic medicines may be eligible for this study.